Outcomes with arsenic trioxide (ATO) in relapsed/refractory patients with acute promyelocytic leukemia (APL).
| Reference . | n . | Induction . | Complete Remission % . | Molecular Remission % . | Median Days to CR . | Post-remission Therapy . | OS % . | DFS % . |
|---|---|---|---|---|---|---|---|---|
| * In this study, 11 newly diagnosed patients were treated with ATO (72% CR), and they account in OS and DFS | ||||||||
| ** OS and DFS are referred to joint analysis (Douer, The Oncologist, 2003) | ||||||||
| † After induction (3/16), after consolidation 2 additional MR | ||||||||
| ‡ Event-Free Survival | ||||||||
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available; SCT, stem cell transplantation; pts, patients | ||||||||
| Shen et al (1997) | 15 | ATO 10 mg/d(5 pts with ATRA or CT) | 93 | NA | 38 | NA | 85 (1y) | 76 (1y) |
| Niu et al (1999) | 31 | ATO* | 84 | NA | 30 | ATO or CT | 50 (2y) | 41 (2y) |
| 11 | ATO + CT | 82 | 35 | or ATO+CT | ||||
| 5 | ATO + ATRA | 100 | 39 | (during 2 years) | ||||
| Soignet et al (1998) | 12 | ATO 0.06–0.2 mg/kg | 82 | 73 | 47 | 5–6 courses ATO 25d (27 pts) or allogeneic SCT +/− ATO (18 pts) | 63 (2y)** | 49 (2y) |
| Soignet et al (2001) | 40 | ATO 0.15 mg/kg | 85 | 86 | 59 | |||
| Shen et al (2001) | 20 | ATO 0.08 mg/kg 28d | 80 | NA | NA | NA | 61 (2y) | 49 (2y) |
| Raffoux et al (2003) (Randomized) | 10 | ATO 0.15 mg/kg | 80 | 19 † | 42 | 1–2 courses ATO 28d (10 pts) | 59 (2y) | 59 (2y) |
| 10 | ATO 0.15 mg/kg+ ATRA 45 mg/m2 | 80 | 42 | or allogeneic SCT (7 pts) or autologous SCT (1 patient) | ||||
| Thomas et al (2005) | 28 | ATO 0.15 mg/kg | 86 | NA | 47 | ATO + CT (11 pts) or SCT (13 pts) | 73 (2y) | 84 (2y) |
| Shigeno et al (2005) | 34 | ATO 0.15 mg/kg | 91 | 72 | NA | ATO 25d × 1 | 56 (2y) | 17 (2y)‡ |
| Reference . | n . | Induction . | Complete Remission % . | Molecular Remission % . | Median Days to CR . | Post-remission Therapy . | OS % . | DFS % . |
|---|---|---|---|---|---|---|---|---|
| * In this study, 11 newly diagnosed patients were treated with ATO (72% CR), and they account in OS and DFS | ||||||||
| ** OS and DFS are referred to joint analysis (Douer, The Oncologist, 2003) | ||||||||
| † After induction (3/16), after consolidation 2 additional MR | ||||||||
| ‡ Event-Free Survival | ||||||||
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available; SCT, stem cell transplantation; pts, patients | ||||||||
| Shen et al (1997) | 15 | ATO 10 mg/d(5 pts with ATRA or CT) | 93 | NA | 38 | NA | 85 (1y) | 76 (1y) |
| Niu et al (1999) | 31 | ATO* | 84 | NA | 30 | ATO or CT | 50 (2y) | 41 (2y) |
| 11 | ATO + CT | 82 | 35 | or ATO+CT | ||||
| 5 | ATO + ATRA | 100 | 39 | (during 2 years) | ||||
| Soignet et al (1998) | 12 | ATO 0.06–0.2 mg/kg | 82 | 73 | 47 | 5–6 courses ATO 25d (27 pts) or allogeneic SCT +/− ATO (18 pts) | 63 (2y)** | 49 (2y) |
| Soignet et al (2001) | 40 | ATO 0.15 mg/kg | 85 | 86 | 59 | |||
| Shen et al (2001) | 20 | ATO 0.08 mg/kg 28d | 80 | NA | NA | NA | 61 (2y) | 49 (2y) |
| Raffoux et al (2003) (Randomized) | 10 | ATO 0.15 mg/kg | 80 | 19 † | 42 | 1–2 courses ATO 28d (10 pts) | 59 (2y) | 59 (2y) |
| 10 | ATO 0.15 mg/kg+ ATRA 45 mg/m2 | 80 | 42 | or allogeneic SCT (7 pts) or autologous SCT (1 patient) | ||||
| Thomas et al (2005) | 28 | ATO 0.15 mg/kg | 86 | NA | 47 | ATO + CT (11 pts) or SCT (13 pts) | 73 (2y) | 84 (2y) |
| Shigeno et al (2005) | 34 | ATO 0.15 mg/kg | 91 | 72 | NA | ATO 25d × 1 | 56 (2y) | 17 (2y)‡ |